David A. Siegel Neoleukin Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.68 - $0.91 $33,796 - $45,227	-49,700 Reduced 21.22%	184,500 $153,000
Q1 2023 May 15, 2023	SELL	$0.5 - $0.72 $8,050 - $11,592	-16,100 Reduced 6.43%	234,200 $163,000
Q4 2022 Feb 14, 2023	SELL	$0.4 - $0.55 $57,480 - $79,035	-143,700 Reduced 36.47%	250,300 $127,000
Q3 2022 Nov 14, 2022	BUY	$0.69 - $1.33 $4,416 - $8,512	6,400 Added 1.65%	394,000 $252,000
Q2 2022 Aug 15, 2022	BUY	$0.92 - $2.25 $90,712 - $221,850	98,600 Added 34.12%	387,600 $399,000
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $93,396 - $283,989	54,300 Added 23.14%	289,000 $543,000
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $279,465 - $465,775	60,100 Added 34.42%	234,700 $1.13 Million
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $695,145 - $1.11 Million	114,900 Added 192.46%	174,600 $1.26 Million
Q2 2021 Aug 16, 2021	SELL	$9.23 - $13.12 $190,138 - $270,272	-20,600 Reduced 25.65%	59,700 $551,000
Q1 2021 May 17, 2021	SELL	$11.26 - $15.78 $594,528 - $833,184	-52,800 Reduced 39.67%	80,300 $988,000
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $543,078 - $777,504	53,400 Added 67.0%	133,100 $1.88 Million
Q3 2020 Nov 16, 2020	BUY	$9.68 - $17.01 $396,880 - $697,410	41,000 Added 105.94%	79,700 $956,000
Q2 2020 Aug 14, 2020	BUY	$9.95 - $17.05 $187,060 - $320,540	18,800 Added 94.47%	38,700 $642,000
Q1 2020 May 15, 2020	SELL	$6.12 - $13.64 $42,228 - $94,116	-6,900 Reduced 25.75%	19,900 $226,000
Q4 2019 Feb 14, 2020	SELL	$2.65 - $12.72 $30,740 - $147,552	-11,600 Reduced 30.21%	26,800 $330,000
Q3 2019 Nov 14, 2019	BUY	$2.33 - $3.76 $89,472 - $144,384	38,400 New	38,400 $109,000

Others Institutions Holding NLTX

# of Institutions

Shares Held

199K

Call Options Held

Put Options Held

Act Capital Management, LLC Wayne, PA

199K
Shares

$0
0.18% of portfolio

View Full List

About Neoleukin Therapeutics, Inc.

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

More about NLTX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account